Estamos realizando la búsqueda. Por favor, espere...
1579
37
170
28929
4401
2598
347
381
Abstract: The rapid development of mRNA-based vaccines against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) led to the design of accelerated vaccination schedules that have been extremely effective in naive individuals. While a two-dose immunization regimen with the BNT162b2 vaccine has been demonstrated to provide a 95% efficacy in naive individuals, the effects of the second vaccine dose in individuals who have previously recovered from natural SARS-CoV-2 infection has not been investigated in detail. In this study, we characterize SARS-CoV-2 spike-specific humoral and cellular immunity in naive and previously infected individuals during and after two doses of BNT162b2 vaccination. Our results demonstrate that, while the second dose increases both the humoral and cellular immunity in naive individuals, COVID-19 recovered individuals reach their peak of immunity after the first dose. These results suggests that a second dose, according to the current standard regimen of vaccination, may be not necessary in individuals previously infected with SARS-CoV-2.
Fuente: Cell Reports, 2021, 36(8), 109570
Editorial: Cell Press Elsevier
Año de publicación: 2021
Nº de páginas: 9
Tipo de publicación: Artículo de Revista
DOI: 10.1016/j.celrep.2021.109570
ISSN: 2211-1247
Url de la publicación: https://doi.org/10.1016/j.celrep.2021.109570
Consultar en UCrea Leer publicación
LOZANO-OJALVO, DANIEL
CAMARA, CARMEN
LOPEZ-GRANADOS, EDUARDO
NOZAL, PILAR
DEL PINO-MOLINA, LUCÍA
BRAVO-GALLEGO, LUZ YADIRA
PAZ-ARTAL, ESTELA
PION, MARJORIE
CORREA-ROCHA, RAFAEL
ORTIZ, ALBERTO
MARCOS LOPEZ HOYOS
IRIBARREN, MARTA ERRO
PORTOLES, JOSE
ROJO-PORTOLES, MARIA PILAR
OJEDA, GLORIA
CERVERA, ISABEL
GONZALEZ-PEREZ, MARIA
BODEGA-MAYOR, IRENE
MONTES-CASADO, MARIA
PORTOLES, PILAR
Volver